PTPI - Petros Pharmaceuticals, Inc.

0.0549
-0.008   -14.572%

Share volume: 5,113,829
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.06
-0.01
-0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 25%
Dept financing 45%
Liquidity 75%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-18.06%
1 Month
-41.78%
3 Months
-85.40%
6 Months
-82.74%
1 Year
-93.97%
2 Year
-94.30%
Key data
Stock price
$0.05
P/E Ratio 
0.00
DAY RANGE
$0.05 - $0.06
EPS 
-$8.38
52 WEEK RANGE
$0.05 - $0.94
52 WEEK CHANGE
-$93.80
MARKET CAP 
3.430 M
YIELD 
N/A
SHARES OUTSTANDING 
7.000 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
2.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,293,418
AVERAGE 30 VOLUME 
$86,743,522
Company detail
CEO: Shulman J. David
Region: US
Website: petrospharma.com
Employees: 20
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Petros Pharmaceuticals, Inc. is based in New York, New York. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED) It also develops and commercializes H100, a patented topical formulation candidate for the. treatment of acute Peyronie's disease.

Recent news
loading